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A commentary on
The activity of SN33638, an inhibitor
of AKR1C3, on testosterone and 17β-
estradiol production and function in
castration-resistant prostate cancer and
ER-positive breast cancer
by Yin YD, FuM, Brooke DG, Heinrich DM,
Denny WA, Jamieson SMF. (2014). Front
Oncol 4:159. doi:10.3389/ fonc.2014.00159
In the current issue of Frontiers in Oncol-
ogy – Cancer Endocrinology Section, Yin
et al. report that the aldo-keto reductase
family 1 member C3 (AKR1C3) inhibitor
SN33638 was able to reduce testosterone
production, PSA expression, and cell pro-
liferation only in some castration-resistant
prostate cancer (CRPC) cells, overexpress-
ing the enzyme, but not the majority of
a panel of prostate and breast cell lines
investigated, and revealing a novel caveat in
developing AKR1C3 inhibitors for cancer
therapy.
Prostate and breast cancers are the most
common cancer and the second-leading
cause of cancer-related deaths in males
and females, respectively (1, 2). The main-
stay treatment for advanced or metastatic
prostate or ER-positive breast carcinoma
is androgen-deprivation therapy or anti-
estrogen therapy. Although initially these
treatments are beneficial and reduce tumor
burden, tumors ultimately become resis-
tant to these therapies. There are few treat-
ment options for this stage of cancers
(termed CRPC and tamoxifen-resistant
breast cancer). Thus, new approaches to
treat or prevent these hormone-insensitive
cancers or their progression are in great
need.
The AKR1C3, also known as 17β-
hydroxysteroid dehydrogenase type 5, is
capable to produce intratumorally testos-
terone and 17β-estradiol by reducing the
androgen precursors and estrone, respec-
tively. The local conversion of less potent
hormones to more potent ones will lead to
nuclear receptor activation and tumor pro-
gression. Therefore, AKR1C3 has recently
been regarded as a potential anti-cancer
drug target in both CRPC and ER-positive
breast cancer (3, 4).
The AKR1C3 inhibitor SN33638 is a
lead compound newly synthesized by Dr.
Jamieson’s group (5). It had low nanomo-
lar potency against AKR1C3 and >300-
fold selectivity for AKR1C3 over the other
AKR1C isoforms. Equipped by this pow-
erful compound, Yin et al. (6) treated
a panel of CRPC and ER-positive breast
cancer cell lines, in the presence of hor-
mone or prostaglandin precursors, prior
to evaluation of cell proliferation and lev-
els of 11β-prostaglandin F2α (11β-PGF2α),
testosterone production, PSA expression,
and cell proliferation (6). They observed
that AKR1C3 mRNA was upregulated in
CRPC in a meta-analysis of patient sam-
ples. 11β-PGF2α and testosterone lev-
els in the cell line panel correlated with
AKR1C3 protein expression. SN33638 pre-
vented 11β-PGF2α formation in cell lines
that expressed AKR1C3, but only par-
tially inhibited testosterone formation and
subsequent cell proliferation and/or PSA
expression only in high (LAPC4 AKR1C3)
or moderate (22RV1) AKR1C3-expressing
cell lines. This may be explained by that
there is AKR1C3-independent steroid hor-
mone production in most cells, and the
data suggest that AKR1C3 is not an effective
drug target in most CRPC cancer patients.
For ER-positive breast cancers, their
finding on AKR1C3 inhibition is even less
promising. They observedAKR1C3 mRNA
was downregulated in patient samples, a
poor correlation between AKR1C3 protein
expression and 17β-estradiol production,
while SN33638 was largely ineffective at
preventing estrone reduction or cell prolif-
eration. These results call into question of
the possibility of using AKR1C3 inhibitors
in treating breast cancer patients.
In summary, Yin et al. (6) revealed a
novel finding that AKR1C3 inhibitor ther-
apy is unlikely to be beneficial for the
treatment of most CRPC and ER-positive
breast cancers. Nevertheless, given the role
of AKR1C3 in intratumoral steroidogene-
sis, we still hold enthusiastically the hope
that a subpopulation of CRPC patients
with high AKR1C3 might benefit from
AKR1C3 inhibitor therapy, whose tumors
are “addicted” from AKR1C3 to produce
testosterone. The study by Yin et al. (6)
provides a valuable framework for future
preclinical or clinical studies aiming at
verifying this hypothesis that AKR1C3
inhibition suppresses tumor formation in
a selected population of AKR1C3-high
CRPC patients.
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